Work Here?
About argenx
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Ghent, Belgium
Founded
2008
Overview
argenx develops treatments for severe autoimmune diseases and cancer through biotechnology. The company focuses on creating therapeutic antibodies, which are proteins designed to target specific diseases. One of their main products, cusatuzumab, is being developed with Janssen R&D to treat blood cancers like leukemia. What sets argenx apart from other companies in the biopharmaceutical market is its strong emphasis on collaboration with academic institutions and industry partners to turn scientific research into effective therapies. The goal of argenx is to provide effective immunology solutions that improve the lives of patients suffering from serious health conditions.
Simplify's Take
What believers are saying
- argenx's cusatuzumab benefits from personalized medicine trends in oncology.
- Steroid-sparing therapeutics collaboration aligns with demand for reduced side effects.
- Advancing multiple Phase 2 trials by 2024 accelerates candidate identification.
What critics are saying
- Increased competition in immunology may impact argenx's market share.
- Failure of efgartigimod in pemphigus could reduce investor confidence.
- Regulatory scrutiny on drug pricing may affect argenx's revenue streams.
What makes argenx unique
- argenx collaborates with Janssen R&D on cusatuzumab for leukemia treatment.
- Focus on autoimmune diseases with innovative FcRn blockers differentiates argenx.
- Partnerships with academic institutions enhance argenx's research capabilities.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$3781.3M
Above
Industry Average
Funded Over
5 Rounds
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 3%2 year growth
↑ 1%argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference.
Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML
Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company Argenx.
$398 million in first quarter global net product sales. FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024. On track to submit filing for pre-filled syringe (PFS) in second quarter 2024
Amsterdam, the Netherlands – argenx (Euronext Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update.A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.Dial-in numbers:Belgium 32 800 50 201. France 33 800 943355. Netherlands 31 20 795 1090
argenx is Hiring for 43 Jobs on Simplify!
Find jobs on Simplify and start your career today
Data & Analytics
2 Open Roles
Content & Writing
2 Open Roles
Legal & Compliance
2 Open Roles
People Also Viewed
Discover companies similar to argenx
About argenx
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Ghent, Belgium
Founded
2008
argenx is Hiring for 43 Jobs on Simplify!
Find jobs on Simplify and start your career today
Data & Analytics
2 Open Roles
Content & Writing
2 Open Roles
Legal & Compliance
2 Open Roles
People Also Viewed
Discover companies similar to argenx